Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
You two obviously have a target buy price. Obvious because you simply protest too much!
Presumably you will change your tune when you have bought in. So I would say just ignore the noise you make in the mean time.
Bozi,
I appreciate who the Diggle brothers are and their background. Must admit to having some admiration for accomplishments and commitments too British science and enterprise. However it seems even they have misjudged this awful market by adding at respective business's at far higher prices. I don't suppose it matters much to them in the long term as they should not be bothered by the day to day share price. Similarly I am ok with it too. I think this has more to do with the UK economic outlook. My concern is not for OBD but the whole of British science. Government need to step up imo.
Looking at the trial protocol under other outcomes.
Immune cell profiling in tumour samples [ Time Frame: For the duration of the study (12 weeks after the final dose of study treatment) ]
Immune cells will be profiled from available biopsy tissue
Other than that we expect RECIST part of the trial to begin and we should expect an RNS
Hi TF & WTP,
It is mainly Scancell department leaders and staff, even including a student. I suppose it underlines the size and breadth of Scancell now and that people are proud of what they are doing and supportive of one another.
Do we not think that the recent local article to Clatterbridge and the Scancell video are simply part of the patient recruitment drive. After all, recruitment is one of, if not the biggest challenge to a successful trial (see COVIDITY). I for one am glad to see Scancell and the CIO doing a thorough job in this respect with ModiFY.
C11/Berm
I wonder if Prof Ottensmeier has more autonomy to talk about the trial as Chief Investigator. He is not employed by Scancell and I would certainly think that he is not bound by AIM or market regulations. Unless his comments are being used as we have seen in a Scancell RNS. Clearly that would need to pass muster with Nomad etc.
So what rules is he bound too? And might we expect something from ASCO. I would remind everybody that Lindy basically gave a pretty clear heads up at the AGM several months prior to official news.
Highly speculative question I know. But a very valid point for discussion I believe...
So this begs the question, as he is Chief Investigator. What is he bound to say or not say. We know that if he is communicating as part of a Scancell RNS then what he say's
Twiggy has a reputation for buying cheap assets. Question is, does that benefit those who bought here around 7 to 9p in the short, medium, or long term? If he 'assists,' with any growth purchase. Do not see how that correlates with other shareholders interests.
Hi,
Thanks WTP for finding this article and posting. Personally I found it heart warming and encouraging and it was an excellent start to my BH weekend. I had a large smile on my face as I read it. Scancell must be proud.
For me, I think the Clatterbridge centre have enabled Trish to take control of, ‘her story.’ That would have been one of the main motivating factors for going to a local newspaper. We did intrude but that is done. Trish has used her own words and that is appropriate IMO.
It just underlines to anybody that could not quite believe this is happening. Well it is!!
Dan re point 1. It is highly unlikely that a second tissue biopsy for the following reasons:
1. Cost
2. Risk of infection
3. The tumor may have been removed
4. The cancer may have changed in between biopsies
5. The clinician may have decided to remove all of the tumour first time round.
A CTC liquid biopsy can be repeated
Thanks TF,
I count SCOPE as effectively still in prep as it appears iSCIB1+ has more potential than the promising SCIB1. Interesting that we can only compare the former preclinical to the latter, a clinically tested sibling! My post was prompted by your question re: ModiFY recruitment. As we know AvidiMab should open up eligibility for SCOPE and therefore once the amended trial is under way, recruitment should be less of an issue.
Once we are on the right track we will get where we are going. Fingers crossed it is worth the journey.
ATB